We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
DIASOURCE (A Biovendor Company)

Download Mobile App




Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

By LabMedica International staff writers
Posted on 31 Jan 2025

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised individuals. More...

One of the major challenges in diagnosing pneumonia is the difficulty in obtaining an appropriate sample, and frequently, no pathogen is identified. Without a clear microbiological diagnosis, broad-spectrum antibiotics are typically administered, which increases the risk of antibiotic resistance and poor patient outcomes if the wrong antibiotics are chosen. The absence of rapid and accurate diagnostic tools only worsens this situation, hindering the ability to provide tailored treatments and leading to the overuse of antibiotics. Researchers are now exploring the possibility of detecting bacterial pneumonia directly from blood samples to improve access to LRTI testing.

Rhode Island Hospital (Providence, RI, USA) has been awarded USD 1 million by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, CARB-X, Boston, MA, USA) to develop a polymerase chain reaction (PCR) method informed by RNA sequencing to detect bacterial pneumonia directly from whole blood. CARB-X is a global non-profit collaboration focused on supporting early-stage research and development of antibacterial therapies to combat the growing problem of antibiotic resistance. The aim is to detect pneumonias caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae, using whole blood samples, making it less invasive compared to traditional methods that require samples from the airways, such as bronchoscopy or deep suctioning.

This simplified approach, involving a needle-stick blood collection from the arm, has the potential to expand access to testing and streamline current LRTI testing methods, enabling testing at primary care centers around the world instead of just tertiary care settings. Unlike traditional microbiological tests, this method will not require specimen culturing, providing results in just four hours. Targeting RNA ensures that the infection is active, as RNA degrades much faster than DNA, lasting only minutes to hours when sourced from bacteria. This technique immediately stabilizes the RNA for testing, and because it targets RNA, it identifies bacteria actively producing resistance proteins, rather than simply detecting bacteria that may carry genes for resistance.

“The support from CARB-X to focus on developing a direct from blood diagnostic for lower-respiratory-tract infections expands our current NIH supported work creating a direct from blood, culture independent, diagnostic for pathogens causing sepsis targeting RNA from the bacteria using RNA sequencing data form patients,” said Sean Monaghan, MD, surgeon at Rhode Island Hospital.

“This innovative diagnostic approach holds the potential to improve access to testing for lower-respiratory-tract infections, including pneumonia, enabling clinicians to make faster, more informed decisions and reduce the use of broad-spectrum antibiotics,” added Erin Duffy, PhD, Chief of R&D and CARB-X. “By supporting Rhode Island Hospital’s work, CARB-X is learning whether alternative sample types in detecting LRTIs is promising for future product development.”

Related Links:
Rhode Island Hospital
CARB-X


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.